ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
|
|
|
|
|
Biotechnology
|
|
$100M–$500M
|
|
(212) 645-2000
|
|
US
|
|
9184
|
|
Monoclonal Antibodies And Biopharmaceutical Company
|
Wu Chen Jia is the CEO of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.
The decision makers in ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company are Alex Pie, Chuck Mellyn, Greg Reynolds, etc. Click to Find ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company decision makers emails.
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company headquarters is located at US.
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company generates an estimated $100M–$500M annually, based on industry analysis and publicly available market data.
You can contact ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company by calling (212) 645-2000.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.